Neuro-Sys and Sciomics announce Partnership Agreement

Neuro-Sys and Sciomics announce a collaboration to co-develop an unrivaled integrated preclinical solution in neurodegenerative disorders.

A NEW STEP FORWARD IN NEURODEGENERATIVE DISEASE RESEARCH

Announcement : Neuro-Sys and Sciomics announce a collaboration to co-develop an unrivaled integrated preclinical solution in neurodegenerative disorders.

December 18, 2019 06:57 PM Eastern Standard Time

GARDANNE, France and HEIDELBERG, Germany – The French biotech company Neuro-Sys SAS and the German biotech company Sciomics GmbH today announced that they are joining their R&D forces to study the proteome and the phosphoproteome in preclinical models of Alzheimer’s, Parkinson’s and ALS diseases to investigate the proteomic and phosphoproteomic profile of these disease models. The aim is to better understand the mechanisms involved in the neurodegenerative process and to provide new solutions for characterizing the efficacy and mode-of-action of neuroprotective compounds.
The changes in the proteome (protein level) and phosphoproteome (phosphorylation status of proteins) will be determined by the scioPhospho platform using advanced in vitro models of Alzheimer’s disease (focused on the chronic and the acute toxicity of the beta amyloid oligomers, AβO), Parkinson’s disease (with a specific attention to the mitochondrial disorders), and amyotrophic lateral sclerosis (focused on the hypersensitivity to glutamate stressor). In addition, the inflammatory component will be analyzed (cytokine release profile).
Identified proteomic changes will be correlated with neuronal survival and proteinopathies detected by immunostaining (e.g. hyperphosphorylation of Tau ; alpha-synuclein aggregation ; translocation of TDP-43).
For many years, we have been thoroughly investigating the mechanisms occurring in these neurodegenerative diseases. We have developed advanced in vitro models of these diseases in which the mechanisms and the pathways involved in the process of death are carefully studied through our intensive internal research and partnerships”, said Noelle Callizot, PharmD, Ph.D., Chief Scientific Officer at Neuro-Sys. “We believe that the collaboration with Sciomics is a great opportunity to better understand pathophysiological pathways and to help our partners in the development of new therapeutic approaches.
Over the last decade we have developed an efficient and robust platform for profiling protein levels and phosphorylation status.”, said Dr. Christoph Schröder, Chief Executive Officer at Sciomics. “By a combination of the profound expertise and advanced pre-clinical models of Neuro-Sys with our in-depth protein readout options, we are looking forward to foster novel insights and developments in the important field of neurodegenerative disorders.

Preliminary results are expected to be released early 2020.

About Neuro-Sys

Neuro-Sys is an expert in preclinical in vitro models of neurodegenerative and neurological diseases. It has developed specific models to accurately determine the pharmacological profiling of lead compounds and explore their underlying mechanism of action. With a great team of experts and an innovative proprietary automated medium throughput platform combined with advanced models, it provides reliable results and a unique approach in the neurodegenerative diseases research.
The company’s many loyal pharma and biotech customers around the world are the best testimony to the efficiency and reliability of its solution.

Contact
Email : This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone : +33 4 1341 5171
http://www.neuro-sys.com

About Sciomics

Sciomics has extensive expertise in the area of biomarker discovery, in vitro as well as in vivo model system characterisation and disease mechanism profiling using its high-content protein and post-translational modification profiling platform in an analysis service setting and for internal research. More than 1,000 proteins are currently analysed by the proprietary fully immuno-based scioDiscover antibody array platform in a single assay with minimal sample requirements. Information on the protein abundance can be combined with the phosphorylation, ubiquitination or methylation status of these proteins. The high-content and high-throughput platform guarantees robust and reproducible results which – due to its immuno-based nature - can easily be translated into validation as well as clinical assays.
The platform’s main applications are the discovery of protein biomarkers, screening and verification of new drug targets, pathway activity profiling as well as drug mode-of-action analysis.

Contact
Email : This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone : +49 6221 4294830
http://www.sciomics.de

 

News

Article | Exploration of Novel Biomarkers for Neurodegenerative Diseases

| December 2024 | Biomarker candidates for neurodegenerative diseases were identified by combining an exploratory proteomic approach with quantitative ligand-binding assays. Sciomics supported this study by proteomic screening of plasma and CSF samples of patients with different neurodegenerative diseases using the scioDiscover microarray platform.

Kenzelmann A, et al.. Exploration of Novel Biomarkers for Neurodegenerative Diseases Using Proteomic Analysis and Ligand-Binding Assays. Biomedicines. 2024;12(12):2794.  
Meeting | Sciomics @ BIO-Europe Spring 25

| March 16-19 2025 | Meet Dr. Christoph Schröder at BIO-Europe Spring in Milano to learn about our biomarker development pipeline and our protein profiling services in pre-clinical research

Article | Altered Serum Proteins indicate Inflammation, Fibrogenesis and Angiogenesis in Fontan Patients

| September 2024 | Four identified serum proteins may advance diagnostic and therapeutic approaches by complementing traditional diagnostic laboratory variables. Sciomics contributed to this study by ScioCD serum analysis targeting diferent CD surface markers, cytokines and chemokines.

Michel M, Renaud D, Schmidt R, et al. Altered Serum Proteins Suggest Inflammation, Fibrogenesis and Angiogenesis in Adult Patients with a Fontan Circulation. International Journal of Molecular Sciences. 2024; 25(10):5416
 
Article | Vago-splenic signal transduction of cardioprotection in humans

| April 2024 | The spleen as a relay organ as well as the vagal innervation determine cardioprotective signal transduction of Remote Ischaemic Conditioning (RIC) and Auricular Tragus Stimulation (ATS). Sciomics contributed to this study by analysing plasma-dialysate samples using the ScioDiscover microarray platform.

Lieder HR, Paket U, Skyschally A, et al. Vago-splenic signal transduction of cardioprotection in humans. Eur Heart J. 2024;45(34):3164-3177. 
Article | Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia

| September 2023 | Article: Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Sciomics supported this study by scioCyto serum analysis in a mouse cancer model.

Taylor, J., Uhl, L., Moll, I. et al. Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Nat Cancer 4, 1544–1560 (2023)

Testimonials

Tara Sigdel, PhD

Associate Professor, Department of Surgery, University of California San Francisco

"We collaborated with Sciomics GmbH in Germany to analyze proteomics data from blood samples of kidney transplant recipients and liver perfusates during normothermic machine perfusion. Throughout the process, Sciomics provided exceptional support, ensuring timely data delivery and valuable assistance with data analysis. Their expertise and commitment have been instrumental in advancing our research, and we are currently using their data in multiple manuscript submissions. I highly recommend Sciomics for their reliable service and expertise in proteomics."

Product: scioDiscover

Dr. Matthew Wright

Chief Scientific Officer, Kinarus Therapeutics AG, Basel, Switzerland

"We are a small biotech company without our own wet labs. Sciomics recommended a UK CRO that performed cell culture experiments for our studies. Sciomics seamlessly coordinated the transfer of the biologic materials to their facility and performed the scioCD panel to characterize cell surface markers and cytokines in cell lines treated with our small molecule drug candidates. The Sciomics data were instrumental in supporting our IP protection strategy. Their advice was very helpful and they worked with us to extract the most out of the data. We are very satisfied and highly recommend the Sciomics platform and the team."

Product: scioCD